Oncology

Question 1

Libtayo: generic name?

Answer 1

Cemiplimab

Question 2

Cemiplimab: brand name?

Answer 2

Libtayo

Question 3

Libtayo: indication?

Answer 3

Advanced cutaneous squamous-cell carcinoma (CSCC)

Question 4

Libtayo: mechanism of action?

Answer 4

PD-1 inhibitor: blocks PD-1 receptor on T-cells, thus preventing cancer cells from connecting and inactivating the T-cell.

Question 5

Libtayo: administration?

Answer 5

350 mg IV, 30 mins every 3 weeks

Question 6

Libtayo: partner?

Answer 6

Regeneron / Sanofi

Question 7

Libtayo: main competition?

Answer 7

Pembrolizumab (Keytruda)

Question 8

Tarlatamab: brand name?

Answer 8

Imdelltra

Question 9

Imdeltra: generic name?

Answer 9

Tarlatamab

Question 10

Tarlatamab: indication?

Answer 10

Investigational:
Small-cell lung cancer (SCLC), after failure of previous treatment(s)

Question 11

Tarlatamab: mechanism of action?

Answer 11

Bispecific T-cell engager (BiTE), attaches to both T-cell (CD3) and cancer cell (DLL-3), brings them together and enhances cancer cell lysis

Question 12

Tarlatamab: administration?

Answer 12

IV 10 mg every 2 weeks

Question 13

Tarlatamab: partner?

Answer 13

Amgen

Question 14

Tarlatamab: adverse effect?

Answer 14

Cytokine-release syndrome (50% of patients, mostly after 1st dose)

Question 15

Cabometyx: generic name?

Answer 15

Cabozantinib

Question 16

Cabozantinib: brand name?

Answer 16

Cabometyx

Question 17

Cabometyx: partner?

Answer 17

Ipsen

Question 18

Cabometyx: Indication(s)?

Answer 18

1. Renal Cell Carcinoma (RCC)
2. Differentiated Thyroid Cancer (DTC)
3. Hepatic Cell Carcinoma (HCC)

Question 19

Cabometyx: administration?

Answer 19

PO

Question 20

Cabometyx: mechanism of action?

Answer 20

MET, AXL and VEGFR blocker (three receptors overexpressed on tumor cells, important for angiogenesis and metastatic spread)

Question 21

Tibsovo: generic name?

Answer 21

Ivosidenib

Question 22

Ivosidenib: brand name?

Answer 22

Tibsovo

Question 23

Tibsovo: partner?

Answer 23

Servier

Question 24

Tibsovo: administration?

Answer 24

PO

Question 25

Tibsovo: indication(s)?

Answer 25

1. AML (with susceptible IDH1 mutation)
2. Cholangiocarcinoma (with susceptible IDH1 mutation) - locally advanced or metastatic

Question 26

Tibsovo: mechanism of action?

Answer 26

IDH-1 inhibitor.
Targets mutant IDH1 enzyme, to decrease 2HG levels and restore normal cell differentiation.

Question 27

Vectibix: generic name?

Answer 27

Panitumumab

Question 28

Panitumumab: brand name?

Answer 28

Vectibix

Question 29

Vectibix: indication(s)?

Answer 29

Metastatic colorectal cancer with wild-type RAS gene

Question 30

Vectibix: partner?

Answer 30

Amgen

Question 31

Vectibix: mechanism of action?

Answer 31

Monoclonal Ab against EGFR